Cofactor Genomics, a clinical-stage company focused on RNA analysis for precision medicine, has received national coverage from Medicare contractor Palmetto GBA for its OncoPrism test. This predictive diagnostic tool analyzes a patient’s tumor immune profile using high-dimensional RNA-based Health Expression Models (HEMs). It predicts a patient’s response to immune checkpoint inhibitor (ICI) immunotherapy, leading to more informed treatment decisions and improved outcomes for cancer patients.
This Medicare coverage decision specifically benefits patients with recurrent and metastatic head and neck squamous cell carcinoma (RM-HNSCC) being considered for ICI immunotherapy, either alone or in combination with chemotherapy. OncoPrism’s effectiveness in predicting patient response to ICI is currently being evaluated in a multicenter national clinical trial called PREDAPT, encompassing eleven solid tumor cancers, including RM-HNSCC.
Cofactor Genomics specializes in utilizing RNA to address critical healthcare challenges. Their PRISM database houses patented HEMs, representing significant advancements in machine learning and RNA analysis. These models leverage vast amounts of biological RNA data to provide insights into biology, disease, and therapy response. Cofactor’s innovative work has earned recognition through publications in prestigious scientific journals and collaborations with numerous healthcare systems. OncoPrism, a CAP/CLIA-validated and Medicare-approved test, exemplifies Cofactor’s commitment to advancing precision medicine through RNA decoding.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
